Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 5/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | NNMT | P40261 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628822 | 0.85 | SLC2A1 (0.65) | SLC2A1PDE4BLMNACSF1RATM | |
| SCHEMBL9875438 | 0.83 | LMNA (0.56) | SLC2A1PDE4BLMNACSF1RATM | |
| SCHEMBL2479384 | 0.81 | LMNA (0.42) | SLC2A1PDE4BLMNACSF1RATM | |
| SCHEMBL3866828 | 0.81 | CSF1R (0.46) | SLC2A1PDE4BLMNACSF1R | |
| SCHEMBL2725311 | 0.81 | HTT (0.49) | SLC2A1PDE4BLMNACSF1RKDM4E | |
| SCHEMBL5929785 | 0.78 | NNMT (0.46) | SLC2A1LMNACSF1RATMNNMT | |
| SCHEMBL3273151 | 0.77 | KDM4E (0.64) | PDE4BLMNACSF1RKDM4E | |
| SCHEMBL4657732 | 0.77 | PDE4B (0.49) | PDE4B | |
| SCHEMBL2706557 | 0.76 | KMT2A (0.47) | SLC2A1PDE4BLMNACSF1RATM | |
| SCHEMBL18318006 | 0.75 | CSF1R (0.49) | SLC2A1CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096884-A1 | 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| US-20080096884-A1 | 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| US-20080096884-A1 | 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| EP-1673086-B1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| EP-1673086-B1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| EP-1673086-A1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030212-A1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030212-A1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096884-A1 | 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors | PDE4A, PDE4B, PDE3B | SLC2A1 4263/4885PDE4B 2/4885LMNA 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.